Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 2/20 | 0.53 |
| ▸ | GRM5 | P41594 | 3/20 | 0.48 |
| ▸ | CDK8 | P49336 | 2/20 | 0.48 |
| ▸ | BRAF | P15056 | 3/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589610 | 0.92 | RAF1 (0.53) | RAF1CDK8BRAF | |
| SCHEMBL3602119 | 0.91 | KDR (0.49) | RAF1CDK8BRAFRET | |
| SCHEMBL3596312 | 0.85 | NPC1 (0.50) | RAF1GRM5CDK8 | |
| SCHEMBL3596314 | 0.83 | GRM5 (0.58) | GRM5 | |
| SCHEMBL3604416 | 0.82 | GRM5 (0.48) | RAF1GRM5CDK8 | |
| SCHEMBL3605396 | 0.82 | KDR (0.54) | RAF1CDK8BRAFRET | |
| SCHEMBL2181161 | 0.81 | GRM5 (0.52) | GRM5 | |
| SCHEMBL6031235 | 0.77 | RAF1 (0.66) | RAF1GRM5CDK8BRAFRET | |
| SCHEMBL3588092 | 0.76 | NPC1 (0.51) | RAF1CDK8BRAF | |
| SCHEMBL4169753 | 0.76 | KDR (0.61) | RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1643991-B1 | BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-7691870-B2 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| EP-1643991-A1 | BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS | MERCK PATENT GmbH (DE) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005004863-A1 | BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | BRAF, RAF1, ARAF | RAF1 2/4885GRM5 3847/4885CDK8 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.